期刊
LUNG CANCER
卷 106, 期 -, 页码 70-75出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2017.02.002
关键词
lmmunotherapy; Pembrolizumab; Nivolumab; First-line; Non-small cell lung cancer
Immune checkpoint inhibitors are considered standard second-line treatment in advanced non-small cell lung cancer patients. This strategy has also become standard in first-line setting for a subgroup of patients with strongly positive PD-Ll tumors; therefore, PD-Ll status might be considered a new biomarker that deserves upfront testing. New combinations of immune checkpoint inhibitors and with chemotherapy have been tested in first-line treatment. However, some questions remain unanswered such as the best treatment strategy or the real upfront efficacy of these therapeutic strategies in the whole lung cancer population. In this review we summarize the main results in the first-line setting of recent phase III trials with immune checkpoint inhibitors in advanced non-small cell lung cancer patients. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据